Back to Search
Start Over
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant gram-negative infections (AIDA)
- Publication Year :
- 2016
-
Abstract
- __Introduction:__ The emergence of antibiotic-resistant bacteria has driven renewed interest in older antibacterials, including colistin. Previous studies have shown that colistin is less effective and more toxic than modern antibiotics. In vitro synergy studies and clinical observational studies suggest a benefit of combining colistin with a carbapenem. A randomised controlled study is necessary for clarification. __Methods and analysis:__ This is a multicentre, investigator-initiated, open-label, randomised controlled superiority 1:1 study comparing colistin monotherapy with colistin-meropenem combination therapy for infections caused by carbapenem-resistant Gramnegative bacteria. The study is being conducted in 6 centres in 3 countries (Italy, Greece and Israel). We include patients with hospital-associated and ventilatorassociated pneumonia, bloodstream infections and urosepsis. The prim
Details
- Database :
- OAIster
- Notes :
- application/pdf, BMJ Open vol. 6 no. 4, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1122525894
- Document Type :
- Electronic Resource
- Full Text :
- https://doi.org/10.1136.bmjopen-2015-009956